2023
Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. BMJ Open 2023, 13: e071688. PMID: 37399447, PMCID: PMC10314648, DOI: 10.1136/bmjopen-2023-071688.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCognitive DysfunctionHIV InfectionsHumansOpioid-Related DisordersPre-Exposure ProphylaxisSubstance Abuse, IntravenousConceptsOpioid use disorderMultiphase optimization strategyCognitive dysfunctionHIV preventionUse disordersPromising biomedical interventionsPre-exposure prophylaxisHIV incidence ratesHIV risk reductionHIV prevention interventionsDrug treatment settingsInstitutional review boardInformed consent formPrEP adherenceHIV prevention contentHIV infectionPrEP uptakeStudy protocolIncidence rateRisk groupsPrevention interventionsPWIDTreatment settingsReview boardEffective interventions
2022
Latent profile analysis of data from the brief inventory of neurocognitive impairment (BINI) to develop neuro-cognitive profiles among opioid-dependent patients in drug treatment
Gunstad J, Disabato D, Shrestha R, Sanborn V, Mistler CB, Copenhaver MM. Latent profile analysis of data from the brief inventory of neurocognitive impairment (BINI) to develop neuro-cognitive profiles among opioid-dependent patients in drug treatment. Journal Of Addictive Diseases 2022, 41: 120-127. PMID: 35615880, PMCID: PMC9699904, DOI: 10.1080/10550887.2022.2080626.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineCognitionCognitive DysfunctionHumansMethadoneOpiate Substitution TreatmentOpioid-Related DisordersConceptsLatent profile analysisNeurocognitive dysfunctionBrief inventoryNeuro-cognitive profileNeuro-cognitive impairmentSelf-reported neurocognitive symptomsProfile analysisOpioid-dependent patientsOpioid use disorderTreatment outcomesNeurocognitive impairmentDrug treatment outcomesMultiple domainsTreatment programUse disordersIntervention strategiesIndividual treatment needsNeurocognitive symptomsDrug treatment settingsTreatment settingsMethadone maintenance treatment programAccommodation strategiesModerate concernMaintenance treatment programOptimal treatment outcomes
2021
Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment
Copenhaver MM, Sanborn V, Shrestha R, Mistler CB, Sullivan MC, Gunstad J. Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment. Drug And Alcohol Dependence 2021, 224: 108726. PMID: 33930640, PMCID: PMC8180490, DOI: 10.1016/j.drugalcdep.2021.108726.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentCognitive dysfunctionRisk scoreDrug treatmentPredictors of MCIOpioid-dependent personsOpioid use disorderPredictive risk scoreMedical chart dataNeuro-cognitive impairmentResource-limited settingsChart dataDrug treatment facilitiesAddiction-related servicesLarger validation studiesPatient demographicsROC curve areaUse disordersTreatment engagementCognitive impairmentPatientsOptimal cutClinical settingLogistic regressionMCI cases
2020
Association between the brief inventory of neurocognitive impairment (BINI) and objective cognitive testing among persons with opioid use disorders in drug treatment
Copenhaver MM, Sanborn V, Shrestha R, Mistler C, Gunstad J. Association between the brief inventory of neurocognitive impairment (BINI) and objective cognitive testing among persons with opioid use disorders in drug treatment. Journal Of Addictive Diseases 2020, 39: 166-174. PMID: 33047651, PMCID: PMC11395862, DOI: 10.1080/10550887.2020.1831129.Peer-Reviewed Original ResearchConceptsMethadone maintenance therapyDrug treatmentNeurocognitive dysfunctionNeurocognitive impairmentOpioid use disorderPossible clinical utilityAccommodation of patientsNIH ToolboxSubjective cognitive dysfunctionMaintenance therapyObjective cognitive testingSpecific neurocognitive profileTreatment outcomesCognitive dysfunctionClinical utilityUse disordersBrief inventoryObjective test performanceDysfunctionCognitive testingCutoff scoreNeurocognitive profileTest batteryObjective performanceImpairment
2016
Treatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment
Shrestha R, Karki P, Huedo-Medina TB, Copenhaver M. Treatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment. Journal Of The Association Of Nurses In AIDS Care 2016, 28: 85-94. PMID: 27769735, PMCID: PMC5183513, DOI: 10.1016/j.jana.2016.09.007.Peer-Reviewed Original ResearchThe Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis
Shrestha R, Weikum D, Copenhaver M, Altice FL. The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. AIDS And Behavior 2016, 21: 1070-1081. PMID: 27544515, PMCID: PMC5318281, DOI: 10.1007/s10461-016-1526-3.Peer-Reviewed Original ResearchConceptsAlcohol use disorderNeurocognitive impairmentUse disordersMalaysia's largest prisonHealth-related qualityNeuropsychological factorsQuality of lifeLargest prisonHIV-InfectedOpioid dependenceHIV treatmentHRQoLImportant negative predictorMeeting criteriaFuture interventionsDepressionNegative predictorPLWHDisordersMalaysian menStandardized scalesImpairmentMediation analysisHRQoL.HIVAn Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy
Copenhaver M, Shrestha R, Wickersham JA, Weikum D, Altice FL. An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. Journal Of Substance Use And Addiction Treatment 2016, 63: 61-65. PMID: 26879859, PMCID: PMC4775373, DOI: 10.1016/j.jsat.2016.01.002.Peer-Reviewed Original ResearchConceptsMethadone maintenance therapyNeuropsychological Impairment ScaleNeurocognitive impairmentMaintenance therapySex-related HIV risk behaviorsHIV risk behaviorsClinical care settingsNeuro-cognitive impairmentExploratory factor analysisCare settingsImpairment ScaleRisk behaviorsAddiction treatmentBrief self-report scaleImpairmentSelf-report measuresSelf-report scalesPatientsPrincipal axis factoringCognitive functioningTherapyFactor analysisOrthogonal varimax rotationPresent studyPotential utility